LOXO-292 Reins In RET-Driven Tumors.
LOXO-292, a selective and potent RET inhibitor, led to tumor shrinkage in RET fusion-positive and RET-mutant cancers alike, according to phase I data reported at the 2018 American Society of Clinical Oncology Annual Meeting.